Get the Stockscreener App
6.84
0.87%
-0.06
After Hours:
6.88
0.04
+0.58%
Mannkind Corp stock is traded at $6.84, with a volume of 2.70M.
It is down -0.87% in the last 24 hours and up +3.01% over the past month.
MannKind Corp is a biopharmaceutical company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. Its approved product, Afrezza (insulin human) Inhalation Powder, is an ultra-rapid-acting inhaled insulin used to improve glycemic control in adults with diabetes. The product consists of a dry powder formulation of human insulin delivered from a small portable inhaler.
See More
Previous Close:
$6.90
Open:
$6.94
24h Volume:
2.70M
Relative Volume:
1.08
Market Cap:
$1.92B
Revenue:
$248.37M
Net Income/Loss:
$11.74M
P/E Ratio:
-36.00
EPS:
-0.19
Net Cash Flow:
$18.24M
1W Performance:
+0.59%
1M Performance:
+3.01%
6M Performance:
+41.91%
1Y Performance:
+87.40%
1-Day Range:
$6.82
$7.005
1-Week Range:
$6.67
$7.04
52-Week Range:
$3.17
$7.63
Mannkind Corp Stock (MNKD) Company Profile
Name
Mannkind Corp
Sector
Industry
Phone
818-661-5000
Address
1 CASPER STREET, DANBURY, CA
Compare MNKD with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
| MNKD | 6.84 | 1.92B | 248.37M | 11.74M | 18.24M | -0.19 |
| VRTX | 450.97 | 116.38B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 738.00 | 82.09B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 605.92 | 36.14B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 244.89 | 31.59B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 113.13 | 27.25B | 3.30B | -501.07M | 1.03B | 11.54 |
Mannkind Corp Stock (MNKD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-10-23 | Initiated | Wedbush | Outperform |
| May-14-21 | Initiated | RBC Capital Mkts | Sector Perform |
| Dec-24-19 | Initiated | Oppenheimer | Outperform |
| Oct-25-19 | Initiated | Cantor Fitzgerald | Overweight |
| May-14-19 | Initiated | BTIG Research | Buy |
| Mar-04-19 | Initiated | SVB Leerink | Outperform |
| Feb-22-19 | Initiated | SVB Leerink | Outperform |
| Feb-28-18 | Downgrade | Maxim Group | Hold → Sell |
| Nov-01-17 | Downgrade | Maxim Group | Buy → Hold |
| Oct-10-17 | Initiated | H.C. Wainwright | Buy |
| Oct-06-17 | Reiterated | Maxim Group | Buy |
| Aug-11-17 | Initiated | Maxim Group | Buy |
| May-10-16 | Reiterated | Piper Jaffray | Underweight |
| May-10-16 | Reiterated | RBC Capital Mkts | Underperform |
| Jan-06-16 | Reiterated | Piper Jaffray | Underweight |
| Jan-06-16 | Reiterated | RBC Capital Mkts | Underperform |
| Nov-04-15 | Downgrade | RBC Capital Mkts | Outperform → Underperform |
| Sep-09-15 | Downgrade | Piper Jaffray | Neutral → Underweight |
| Aug-03-15 | Reiterated | RBC Capital Mkts | Outperform |
| May-11-15 | Downgrade | JP Morgan | Neutral → Underweight |
| May-11-15 | Reiterated | MLV & Co | Hold |
| Apr-16-15 | Reiterated | RBC Capital Mkts | Outperform |
View All
Mannkind Corp Stock (MNKD) Latest News
MannKind (STU:NNFN) Inventories, Raw Materials & Components : €5.8 Mil (As of Sep. 2024) - GuruFocus.com
MannKind Shares Soar to Over 8-Year Highs on United Therapeutics’ Tyvaso Revenue Surge: Retail Is Optimistic - MSN
MannKind Corp director Steven Binder sells $456,563 in stock - Investing.com
Insulin Pump Market Report 2024-2035, Featuring Profiles of Leading Players Including Beta Bionics, CeQur, EOFlow, Insulet, LA Roche, MannKind, Medtronic, Medtrum Technologies and MicroPort - Yahoo Finance
MannKind Corporation (NASDAQ:MNKD) Q3 2024 Earnings Call Transcript - Insider Monkey
MannKind Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance
Insider Sale: Chief People & Workpl Officer Stuart Tross Sells 5 - GuruFocus.com
MannKind Corp's chief people officer Stuart Tross sells $403,700 in stock - Investing.com Australia
Earnings call: MannKind sees growth and pipeline progress in Q3 2024 - Investing.com
MannKind Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Pulmatrix Announces Third Quarter 2024 Financial Results and Provides Corporate Update - Quantisnow
MannKind Corp (MNKD) Q3 2024 Earnings Call Highlights: Strong Re - GuruFocus.com
MannKind Corp (MNKD) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic ... - Yahoo Finance
MannKind (MNKD) Q3 2024 Earnings Call Transcript - Yahoo! Voices
MannKind (MNKD) Reports Q3 Earnings: What Key Metrics Have to Say - Yahoo Finance
MannKind Corp Q3 2024 Earnings: EPS of $0.04 Beats Estimates, Re - GuruFocus.com
MannKind (MNKD) Matches Q3 Earnings Estimates - Yahoo Finance
MannKind: Q3 Earnings Snapshot - Thehour.com
MannKind stock soars to 52-week high, hits $7.38 - Investing.com
MannKind Corp (MNKD) Q3 2024 Earnings Report Preview: What To Lo - GuruFocus.com
MannKind Corp (MNKD) Q3 2024 Earnings Report Preview: What To Look For - Yahoo Finance
International Assets Investment Management LLC Raises Position in MannKind Co. (NASDAQ:MNKD) - MarketBeat
MannKind (NASDAQ:MNKD) Reaches New 1-Year HighWhat's Next? - MarketBeat
MannKind Stock Surge Pre-Market Fueled by Promising Nintedanib DPI Trial Results, Driving Retail Optimism - Barchart
Creative Planning Reduces Position in MannKind Co. (NASDAQ:MNKD) - Defense World
MannKind Corporation (MNKD) Hits Fresh High: Is There Still Room to Run? - Yahoo Finance
First Site Initiated in Australia for MannKind’s Phase 3 Clinical Trial Evaluating Clofazimine Inhalation Suspension for the Treatment of Nontuberculous Mycobacterial (NTM) Lung Disease - ForexTV.com
MannKind (NASDAQ:MNKD) Sets New 1-Year HighTime to Buy? - MarketBeat
MannKind stock soars to 52-week high, touches $6.93 - Investing.com
MannKind Co. (NASDAQ:MNKD) Receives Consensus Rating of "Buy" from Brokerages - MarketBeat
MannKind Corporation Reports 2012 Fourth Quarter and Full Year Financial Results - AOL
SG Americas Securities LLC Takes Position in MannKind Co. (NASDAQ:MNKD) - MarketBeat
Mannkind Corp (MNKD) receives an Outperform rating from Leerink Partners - Knox Daily
Recent Insider Activity Could Benefit 3M Co. (MMM) - Knox Daily
Holdings of Mannkind Corp (MNKD) are aligned with the stars - SETE News
Selling Buzz: Mannkind Corp [MNKD] Chief People & Workpl Officer Tross Stuart A sells 25,000 shares of the company - Knox Daily
Ratios Revealed: Decoding Mannkind Corp (MNKD)’s Financial Health - The Dwinnex
MannKind Corp (MNKD) Q2 2024 Earnings Call Highlights: Record Revenue and Strategic Pipeline ... By GuruFocus - Investing.com Canada
MannKind Corp (MNKD) Q2 2024 Earnings Call Highlights: Record Revenue and Strategic Pipeline ... - Yahoo Finance
MannKind Corp (MNKD) Q2 2024 Earnings Call Highlights: Record Re - GuruFocus.com
Did Mannkind Corp (MNKD) perform well in the last session? - US Post News
Potential Price Increase for Mannkind Corp (MNKD) After Recent Insider Activity - Knox Daily
Mannkind Corp (MNKD) can make a big difference with a little luck - SETE News
Squarepoint Ops LLC Sells 133,926 Shares of MannKind Co. (NASDAQ:MNKD) - MarketBeat
Why MannKind (MNKD) Could Beat Earnings Estimates Again - Yahoo Finance
MannKind (MNKD) Just Overtook the 20-Day Moving Average - Yahoo Finance
MannKind Co. (NASDAQ:MNKD) Shares Purchased by Millennium Management LLC - MarketBeat
MannKind (NASDAQ:MNKD) Shares Up 3.2% - MarketBeat
MannKind Leverages Tyvaso DPI Strength In Pulmonary Market Expansion - Seeking Alpha
Marshall Wace LLP Sells 205,764 Shares of MannKind Co. (NASDAQ:MNKD) - MarketBeat
A better buy-in window may exist right now for Mannkind Corp (MNKD) - SETE News
Mannkind Corp Stock (MNKD) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.89%
2.08%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):